About Agenovir

Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with, or caused by, latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited.

Using its deep virology expertise and targeted genome editing technologies, Agenovir’s mission is to develop innovative treatments that disrupt or eliminate pathogenic viral genomes, bringing hope to patients who suffer from devastating, persistent viral infection. Agenovir is headquartered in South San Francisco, CA.

Agenovir Highlights
  • Experienced and successful leadership team
  • Industry leading scientific advisory board
  • First mover on CRISPR/Cas9-based antiviral therapeutics
  • Significant market opportunity across Agenovir portfolio
  • Broad IP related to nuclease-based antiviral therapeutics
January 31, 2017

Agenovir Names Bolyn Hubby, Ph.D., as Chief Scientific Officer


Diseases Associated with Viral Reservoirs

Agenovir is developing therapies to target and disrupt viral DNA. By interfering at the level of DNA, it may be possible to treat and eliminate latent viruses and persistent viral reservoirs for which there are no current treatments.


Human Papillomavirus


Epstein-Barr Virus




Hepatitis B


Herpes Simplex Virus


Varicella Zoster Virus

A virus is an infectious agent that replicates only inside the living cells of other organisms. Once a virus has entered a host, it may betray its presence to the immune system by directing the synthesis of foreign viral proteins. Many viruses, however, enter a state of latency during which replication stops or slows. In this latent state, the virus is less likely to be detected and eliminated by the immune system.

A latent virus can remain in a host indefinitely, oftentimes within a viral reservoir, a cell type or anatomical site where a virus accumulates and persists. Because the viral genome is not fully eradicated by the host’s immune system, the virus may reactivate periodically. In the case of Herpes simplex virus (“HSV”), the virus reactivates occasionally to cause cold sores.

More serious ramifications of latent viral infection include the possibility of transforming the cell or forcing the cell into uncontrolled division. This is caused by insertion of the viral genome into the host’s own genes and by expression of host cellular growth factors that benefit the virus. This is seen with human papilloma virus (“HPV”) where persistent infection may lead to cervical or anal cancer resulting from cellular transformation.

While antiviral therapies can suppress active viral replication, no existing treatment can effectively eradicate latent infection. During latent infection, the dormant viral genome provides few therapeutic targets other than itself for antiviral drug development, and therefore a cure is lacking for many viral diseases of critical unmet medical need.

Important Notice

Notice: We do not have approval from the U.S. Food and Drug Administration or any other governmental agency, whether in the U.S. or abroad, to sell or market any product to treat or cure any disease or condition, including our drug candidates that we hypothesize may, following further study, clinical trials and all required approvals, be used to treat diseases associated with Human Papillomavirus (“HPV”), Cytomegalovirus (“CMV”), Hepatitis B (“HBV”), Herpes Simplex Virus (“HSV”), Epstein-Barr Virus (“EBV”), or Varicella Zoster Virus (“VZV”), including but not limited to Cervical Cancer, Anal Cancer, Skin and Genital Warts, or EBV and CMV Infection in Transplant Recipients. Our drug candidates have not completed the approval process (including, but not limited to clinical trials) that is required by the U.S. Food and Drug Administration. Our drug candidates have not been proven safe and effective and may not receive U.S. Food and Drug Administration approval. We do not currently sell any drug products or other treatments.


Agenovir is using state-of-the-art CRISPR/Cas9 and other nucleases designed, engineered, and simulated in silico to to disrupt intracellular viral DNA. By disrupting viral DNA, it may be possible to treat and eliminate persistent viral reservoirs.

Agenovir’s unique CRISPR/Cas9 strategy does not require donor DNA or host repair. The targeted disruption of viral genes is anticipated to be sufficient to kill or cure an infected cell. As a proof of concept, Agenovir has generated in vitro data for several viruses, including HPV and EBV, that demonstrate infection-specific cell death following delivery of nucleases to human cells.

Agenovir was founded based on technology developed in the laboratory of Stephen Quake, Ph.D., a professor of Bioengineering and Applied Physics at Stanford University.

Guide RNA
Target Viral DNA
Cas9 protein

Cas9 protein bound to CRISPR RNA and target viral DNA.


The Agenovir team is at the cutting edge of scientific research, leading the industry in developing a new and innovative approach to treat persistent viral diseases that we believe will fundamentally change the therapeutic paradigm.

Dirk Thye, M.D.

President and CEO

Bolyn Hubby, Ph.D.

Chief Scientific Officer

Derek Sloan, M.D.

Director, Research

William M. Smith, J.D., M.P.A.

Director, Intellectual Property

Stephen Quake, Ph.D.

Founder, Chair of the Scientific Advisory Board

News and Insights

Learn More

Targeted viral genome editing